Key Takeaways:
- Kardigan aims to raise up to $373.3 million in its US IPO
- The biotech is advancing three late-stage cardiovascular therapies
- Shares will list on the Nasdaq under the ticker "KARD"
Back
Kardigan targets $1.4 billion valuation in US biotech IPO
Kardigan, a clinical-stage biotech developing precision medicines for cardiovascular diseases, is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the company said Thursday.
The Princeton, New Jersey-based company plans to raise as much as $373.3 million by offering 23.3 million shares at a price range of $14 to $16 each, according to its IPO filing. The offering is being underwritten by J.P. Morgan, Jefferies, Leerink Partners and TD Cowen.
Kardigan's pipeline centers on three late-stage experimental therapies targeting distinct cardiovascular conditions. Danicamtiv is being developed for genetic dilated cardiomyopathy, a condition where the heart's pumping ability is impaired. Ataciguat targets calcific aortic valve stenosis, a narrowing of the aortic valve that affects roughly 2% of adults over 65. Tonlamarsen, designed to suppress hepatic angiotensinogen production, is being studied for blood pressure management in acute severe hypertension.
The company operates in a cardiovascular drug market projected to exceed $80 billion annually, where precision medicine approaches remain underpenetrated. Unlike broad-spectrum heart failure drugs such as Novartis's Entresto, which generated $6.4 billion in 2025 sales, Kardigan's candidates target genetically defined patient subgroups — a strategy that could improve trial success rates but narrow the addressable market for each asset.
Cardiovascular disease remains the leading cause of death globally, accounting for nearly 18 million deaths per year, according to the World Health Organization. The push toward genetically stratified therapies mirrors trends seen in oncology, where biomarker-driven drugs have commanded premium pricing and higher approval rates from the US Food and Drug Administration.
Kardigan's IPO comes during a measured recovery in biotech listings after a prolonged downturn. The Renaissance IPO Index, which tracks newly public companies, has gained roughly 12% year-to-date, though biotech IPOs remain selective. The company's cash position and burn rate were not disclosed in the filing.
The company will list on the Nasdaq under the ticker symbol "KARD."
This article is for informational purposes only and does not constitute investment advice.
